Study unveils novel pathway triggering immune response to DNA damage

Bio­Car­dia has paused en­roll­ment in a piv­otal study of its stem cell ther­a­py for heart fail­ure af­ter an in­de­pen­dent re­view board de­ter­mined the tri­al was

Share this article The indicated that the accelerated approval pathway could be an option for marketing due to positive clinical evidence. Image credit: Shutterstock/nobeastsofierce. Mesoblast’s

Plus, news about Con­ver­gent Ther­a­peu­tics, Turn­stone Bi­o­log­ics and Son­net Bio­Ther­a­peu­tics: Lyra Ther­a­peu­tics paus­es de­vel­op­ment of chron­ic rhi­nos­i­nusi­tis drug: The com­pa­ny Sign up to read this